The strength of the study is the first systematic review on hepcidin in AL/HCT patients with a new insight into the assessment of serum hepcidin levels in pediatric and adult patients, showing variability in serum profile before, during, and after AL/HCT treatment. The gene discussed is HAMP; the disease is axial length measurement.